Volta Medical—a company that develops artificial intelligence (AI) solutions to assist electrophysiologists—has announced the appointment of Bill Hoffman as executive chairman of its board of directors.
A press release states that Hoffman “brings a track record of guiding innovative startups to global success”.
As former chief executive officer (CEO) of Inari Medical, Hoffman oversaw its growth from early-stage concept to a publicly traded company with more than US$500 million in revenue and a significant clinical impact in venous thromboembolism treatment. Inari was acquired by Stryker for US$4.9 billion in February 2025.
“We are honoured to welcome Bill Hoffman as executive chairman,” said Théophile Mohr-Durdez, CEO and co-founder of Volta. “Bill’s experience building, commercialising and scaling disruptive medical technologies will be invaluable as we accelerate global access to our AI-driven solutions for cardiac ablation.”
“Volta’s technology has demonstrated—for the first time in the history of ablation—a clinically important and statistically significant improvement in efficacy outcomes for patients with atrial fibrillation,” Hoffman commented. “How cool is that? I am so excited to join the Volta team and mission to impact our patients in the most amazing ways.”
In addition to Hoffman’s appointment, Volta’s board has appointed Jerome Kalifa to the role of executive vice chairman. Kalifa will also continue to serve in the role of chief medical officer.
“We are excited to work with Bill on this mission,” Kalifa added. “We are committed to eliminating atrial fibrillation, impacting as many patients as possible, as fast as possible.”
These leadership appointments follow the recent publication of the landmark TAILORED-AF clinical trial in Nature Medicine, which demonstrated that an AI-guided procedure using Volta’s technology—in combination with conventional pulmonary vein isolation (PVI)—resulted in significantly improved outcomes for patients with persistent atrial fibrillation compared to PVI alone.
